Virpax Pharmaceuticals Inc (NASDAQ:VRPX) — Market Cap & Net Worth
Market Cap & Net Worth: Virpax Pharmaceuticals Inc (VRPX)
Virpax Pharmaceuticals Inc (NASDAQ:VRPX) has a market capitalization of $273.35K ($273.35K) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31253 globally and #6307 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Virpax Pharmaceuticals Inc's stock price $0.22 by its total outstanding shares 1242500 (1.24 Million). Also see how large is Virpax Pharmaceuticals Inc's balance sheet for a full breakdown of the balance sheet.
Virpax Pharmaceuticals Inc Market Cap History: 2021 to 2025
Virpax Pharmaceuticals Inc's market capitalization history from 2021 to 2025. Data shows change from $42.62 Million to $273.35K (-73.76% CAGR). Also see Virpax Pharmaceuticals Inc (VRPX) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Virpax Pharmaceuticals Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #921 of 976 |
Weight: Virpax Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Virpax Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Virpax Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Virpax Pharmaceuticals Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of VRPX by Market Capitalization
Companies near Virpax Pharmaceuticals Inc in the global market cap rankings as of September 18, 2026. Review how tangible is Virpax Pharmaceuticals Inc's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Virpax Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Virpax Pharmaceuticals Inc Historical Marketcap From 2021 to 2025
Between 2021 and today, Virpax Pharmaceuticals Inc's market cap moved from $42.62 Million to $ 273.35K, with a yearly change of -73.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $273.35K | -42.09% |
| 2024 | $472.03K | -88.13% |
| 2023 | $3.98 Million | -48.55% |
| 2022 | $7.73 Million | -81.87% |
| 2021 | $42.62 Million | -- |
End of Day Market Cap According to Different Sources
On May 19th, 2026 the market cap of Virpax Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $273.35K USD |
| MoneyControl | $273.35K USD |
| MarketWatch | $273.35K USD |
| marketcap.company | $273.35K USD |
| Reuters | $273.35K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Virpax Pharmaceuticals Inc
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an … Read more